INTRODUCTION {#sec1}
============

Lower respiratory tract infections (LRTIs) are a major cause of morbidity in infants and children worldwide. The respiratory syncytial virus (RSV), influenza, the human parainfluenza virus ([@ref1]), and the human metapneumovirus ([@ref2]) are several of the viruses responsible for LRTI hospitalization in infants. RSV, an enveloped single-stranded RNA virus of the *Paramyxoviridae* virus family, is the most common cause of LRTI in children below one year of age ([@ref3]).

The respiratory syncytial virus is transmitted by aerosolized droplets or by direct contact with secretions or contaminated surfaces ([@ref3]). The incubation period for RSV is 2-8 days on average ([@ref3]). Initial symptoms of infection include congestion and coryza (rhinitis), often accompanied by a lowgrade fever; at this point, RSV is usually confined to the nasopharynx. However, 2--5 days after the onset of symptoms, the infection may spread to the lower respiratory tract ([@ref4]).

Virtually all individuals experience RSV infection within the first two years of life, usually within the first 12 months ([@ref3]). This initial infection is symptomatic for bronchiolitis and pneumonia in 25% to 40% of infants and young children ([@ref5]). Fortunately, most infants and young children who are symptomatic for RSV infection recover fully in 8 to 15 days; however, 0.5% to 2% of all infants and young children require hospitalization during their first RSV infection ([@ref6]).

Infants with pre-existing diseases are at an increased risk of a serious debilitating disease during the RSV season. Bronchopulmonary dysplasia and a congenital heart disease are examples of conditions that increase the risk of serious RSV complications in infants. Other risk factors include pulmonary consolidation on chest radiography, premature birth, and hospitalization during the RSV season (the risk correlates directly with the length of hospital stay) ([@ref7]). Such environmental factors as exposure to passive cigarette smoke and crowded living conditions also increase the risk of serious RSV complications.

RSV infection is highly predictable on an annual basis. The time of year when RSV outbreaks usually occur is called the RSV season. In the Northern Hemisphere, the RSV season begins in October and ends in April ([@ref8]).

An epidemiologic survey was conducted in Central Eastern European (CEE) region to characterize the onset, peak, and duration of the RSV season, as well as the incidence and the outcome of hospitalization due to LRTIs caused by RSV in children below one year of age. The main results of this study have been published elsewhere ([@ref9]). Here we present the data on a selected sample of children below one year of age hospitalized with LRTI (age distribution, risk factors, need for a supportive treatment, and outcome of hospitalization) in two Baltic countries -- Lithuania and Estonia.

METHODS {#sec2}
=======

This was a retrospective, cross-sectional, observational, multi-country epidemiologic survey conducted in 12 countries of the CEE region (Bosnia/Herzegovina, Bulgaria, Croatia, the Czech Republic, Estonia, Hungary, Lithuania, Romania, Serbia, Slovakia, Slovenia, and Ukraine). The protocol of the survey was reviewed and approved by national ethics committees. The population studied included children with LRTI, below one year of age, who were admitted to participating hospitals between October 2009 and April 2010 and/or October 2010 and April 2011 (two consecutive RSV seasons).

Eligible subjects were children below one year of age, hospitalized for LRTI (bronchiolitis, pneumonia), and for whom rapid diagnostic test (RDT) for RSV was performed. The following exclusion criteria were applied: children above one year of age and children without information on gestational age, gestational body weight, dates of hospitalization and hospital discharge, and the outcome of hospitalization. For each enrolled patient, informed consent was obtained from the parents, guardians, or legal representatives.

Selection of investigators was based on their prior research experience, expertise in the care of children with LRTI, ability to appropriately perform the survey, and their overall interest in participating in this study. Physicians at Children's Hospital Affiliate of Vilnius University Hospital Santaros Klinikos (\<50 beds for infants below one year of age available) and Tallinn Children's Hospital, equipped with 35 beds, participated in this survey.

On the day of hospital discharge or during the first check-up visit after LRTI hospitalization, a physician completed a study questionnaire requesting the following information: demographics (gender, age, gestational age, gestational weight and height), risk factors, patient status at admission, RSV diagnostic procedure, treatment course, and the outcome of disease. The Lithuanian site reported the application of an immunochromatographic method (e.g., BD Directigen RSV, RSV Respi-Strip), whereas the Estonian site applied an immunofluorescense and polymerase chain reaction method to test for RSV infection.

Descriptive statistics were applied for data analysis. Statistical software SAS 9.1.2 (SAS Institute, Cary, NC, USA) was used for statistical data analysis.

RESULTS {#sec3}
=======

In total, 3841 records were collected in the 12 participating countries during both seasons, with 3474 cases (90.4%) fulfilling the case definition (i.e., children less than one year of age hospitalized with a diagnosis of bronchiolitis and/or pneumonia within the observational periods). Of this number, 258 case report forms were completed at the Lithuanian site and 289 case report forms were completed at the Estonian site. Among them, four Lithuanian records (1.6%) and 61 Estonian records (21.1%) did not fulfil the case definition of this survey and were not included in the analysis. This resulted in 254 Lithuanian and 228 Estonian documented records fulfilling the definition for an LRTI case, which accounted for 13.9% of the entire survey population. A total of 297 LRTI cases were recorded in season 1 (October 2009--April 2010) and 185 cases were recorded in season 2 (October 2010--April 2011). [Table 1](#T1){ref-type="table"} presents the time course of case collection during both seasons in each country separately.

Patient characteristics are summarized in [Table 2](#T2){ref-type="table"}. Male patients accounted for slightly more than half of all documented LRTI cases (58.3% in Lithuania and 56.1% in Estonia). The majority of hospitalized LRTI patients were less than six months of age. The proportion of premature infants (gestational age of ≤36 weeks) accounted for just over 10% of documented LRTI cases in Lithuania and Estonia; this proportion was almost two times lower than that in the entire survey population (21.8%). The prevalence of concomitant chronic diseases at admission in both Baltic countries was also considerably lower ([Table 2](#T2){ref-type="table"}) than the rates in the full survey population.

###### 

Time course of recorded LRTI cases and RSV-positive cases[\*](#TF1){ref-type="table-fn"}

  Time period     Lithuania (*n* = 254)   Estonia (*n* = 228)   Entire survey population (*N* = 3474)                       
  --------------- ----------------------- --------------------- --------------------------------------- ------------ ------ ------------
  Season 1        177                     108 (61.0)            120                                     96 (80.0)    1499   567 (37.8)
  October 2009    0                       0                     0                                       0            8      0
  November 2009   2                       1 (50.0)              3                                       1 (33.3)     68     8 (11.8)
  December 2009   9                       4 (44.4)              1                                       0            125    13 (10.4)
  January 2010    26                      13 (50.0)             10                                      8 (80.0)     215    62 (28.8)
  February 2010   63                      42 (66.7)             27                                      23 (85.2)    388    168 (43.3)
  March 2010      56                      38 (67.9)             47                                      37 (78.7)    466    209 (44.8)
  April 2010      21                      10 (47.6)             32                                      27 (84.4)    229    107 (46.7)
  Season 2        77                      29 (37.7)             108                                     103 (95.4)   1975   856 (43.3)
  October 2010    1                       0                     0                                       0            135    46 (34.1)
  November 2010   0                       0                     0                                       0            311    109 (35.0)
  December 2010   2                       0                     5                                       5 (100.0)    419    197 (47.0)
  January 2011    9                       3 (33.3)              6                                       6 (100.0)    380    172 (45.3)
  February 2011   8                       2 (25.0)              10                                      10 (100.0)   281    117 (41.6)
  March 2011      30                      10 (33.3)             48                                      46 (95.8)    276    138 (50.0)
  April 11        27                      14 (51.9)             39                                      36 (92.3)    173    77 (44.5)

LRTI -- lower respiratory tract infection; RSV -- respiratory syncytial virus.

\* Values presented are number or number (%).

† Percentage of RSV-positive cases in relation to LRTI cases with the RSV rapid diagnostic test.

###### 

General characteristics of patients[\*](#TF3){ref-type="table-fn"}

  Patient characteristics        Lithuania (*n* = 254)   Estonia (*n* = 228)   Entire survey population (*N* = 3474)
  ------------------------------ ----------------------- --------------------- ---------------------------------------
  Sex                                                                          
  Female                         99 (39.0)               92 (40.4)             1409 (40.6)
  Male                           148 (58.3)              128 (56.1)            2024 (58.3)
  Unknown                        7 (2.8)                 8 (3.5)               41 (1.2)
  Age at admission                                                             
  0-6 months                     192 (75.6)              157 (68.9)            2400 (69.1)
  6-12 months                    62 (24.4)               71 (31.1)             1074 (30.9)
  Gestational age                                                              
  ≤28 weeks                      4 (1.6)                 9 (3.9)               121 (3.5)
  29-32 weeks                    11 (4.3)                6 (2.6)               233 (6.7)
  33-36 weeks                    16 (6.3)                16 (7.0)              403 (11.6)
  ≥37 weeks                      214 (84.3)              197 (86.4)            2679 (77.1)
  Unknown                        9 (3.5)                 0                     38 (1.1)
  Mean (SD) birth weight, g      3367 (723)              3291 (776)            2998 (841)
  Birth weight                                                                 
  \<1000g                        2 (0.8)                 5 (2.2)               101 (2.9)
  1000-\<1500g                   6 (2.4)                 7 (3.1)               176 (5.1)
  1500-\<2500g                   21 (8.3)                16 (7.0)              482 (13.9)
  2500-\<4200g                   205 (80.7)              184 (80.7)            2592 (74.6)
  \>4200 g                       20 (7.9)                16 (7.0)              114 (3.3)
  Mean (SD) birth height, cm     52 (4)                  50 (4)                49 (5)
  Concomitant chronic diseases                                                 
  Any chronic disease            11 (4.3)                11 (4.8)              591 (17.0)
  Congenital heart disease       5 (2.0)                 7 (3.1)               166 (4.8)
  Bronchopulmonary dysplasia     2 (0.8)                 4 (1.8)               145 (4.2)
  Neuromuscular disease          1 (0.4)                 0                     108 (3.1)
  Other chronic diseases         10 (3.9)                5 (2.2)               331 (9.5)
  RSV prophylaxis                1 (0.4)                 0                     68 (2.0)

RSV -- respiratory syncytial virus.

\* All values are *n* (%) unless otherwise stated.

At admission, bronchiolitis was the most common diagnosis of LRTI cases in both countries; pneumonia was diagnosed in about 15% of LRTI cases ([Table 3](#T3){ref-type="table"}). Considerable differences between the two countries were observed in the state of consciousness on admission. In Lithuania, 36.6% of hospitalized cases were alert and conscious at admission, whereas in Estonia, 83.3% of cases were conscious at admission.

RSV rapid tests were performed for all documented LRTI cases in Estonia and for 99.6% cases in Lithuania. The aetiology of RSV was confirmed in 87.3% of the tested LRTI cases in Estonia. In Lithuania, the proportion of confirmed RSV cases was lower (54.2%) and was closer to the rates observed in the full survey population (42.4%).

###### 

Admission diagnosis and performance of an RSV rapid test[\*](#TF4){ref-type="table-fn"}

  Clinical features on admission         Lithuania (*n* = 254)   Estonia (*n* = 228)   Entire survey population (*N* = 3474)
  -------------------------------------- ----------------------- --------------------- ---------------------------------------
  Admission diagnosis                    214 (84.3)              192 (84.2)            1983 (57.1)
  Bronchiolitis only                                                                   
  Pneumonia only                         40 (15.7)               35 (15.4)             1183 (34.1)
  Bronchiolitis and pneumonia            0                       1 (0.4)               308 (8.9)
  States of consciousness on admission                                                 
  Alert                                  93 (36.6)               190 (83.3)            1974 (56.8)
  Agitated/irritable                     120 (47.2)              19 (8.3)              1025 (29.5)
  Somnolent                              38 (15.0)               18 (7.9)              274 (7.9)
  Soporous                               2 (0.8)                 0                     35 (1.0)
  Comatose                               0                       0                     15 (0.4)
  Unknown                                1 (0.4)                 1 (0.4)               151 (4.3)
  Performance of RSV test                253 (99.6)              228 (100.0)           3354 (96.5)
  Confirmed RSV infection                137 (54.2)              199 (87.3)            1423 (42.4)

RSV -- respiratory syncytial virus.

\* All values are *n* (%) unless otherwise stated.

The mean duration of hospital stay was ten days in Lithuania and seven days in Estonia. In this study, more than 40% of patients with LRTIs in Lithuania and over 30% of cases in Estonia stayed in hospital longer than one week. Intensive care unit (ICU) hospitalization was required for 9.1% of LRTI cases in Lithuania and in 3.1% of cases in Estonia. In LRTI cases transferred to the ICU, the mean duration of stay in the ICU was six days in Lithuania and four days in Estonia ([Table 4](#T4){ref-type="table"}). Supplemental oxygen was required for 23.2% of LRTI cases in Lithuania and 31.6% of LRTI cases in Estonia. In LRTI cases with supplemental oxygen administration, the mean duration of oxygen administration was seven days in Lithuania and three days in Estonia. The majority of patients with LRTIs received treatment with bronchodilatators ([Table 4](#T4){ref-type="table"}). In Lithuania, complete recovery at discharge was assessed for 35.8% of LRTI cases and improvement was observed in 62.2% of cases. In Estonia, all LRTI cases were improved at discharge, and there were no complete recoveries.

###### 

Treatment characteristics and outcome of LRTI cases

                                                                          Lithuania (*n* = 254)   Estonia (*n* = 228)   Entire survey population (*N* = 3474)
  ----------------------------------------------------------------------- ----------------------- --------------------- ---------------------------------------
  Mean (SD) duration in hospital, days                                    10 (14)                 7 (3)                 11 (12)
  Duration of hospitalization (categorical), *n* (%)                                                                    
  1-3 days                                                                34 (13.4)               24 (10.5)             224 (6.4)
  4-7 days                                                                115 (45.3)              126 (55.3)            1360 (39.1)
  8-14 days                                                               85 (33.5)               73 (32.0)             1408 (40.5)
  ≥15 days                                                                19 (7.5)                4 (1.8)               470 (13.5)
  Unknown                                                                 1 (0.4)                 1 (0.4)               12 (0.3)
  ICU hospitalization, *n* (%)                                            23 (9.1)                7 (3.1)               671 (19.3)
  Mean (SD) duration of ICU hospitalization, days                         6 (5)                   4 (2)                 11 (14)
  Duration of ICU hospitalization (categorical), *n* (%)                                                                
  1-3 days                                                                13 (5.1)                4 (1.8)               174 (5.0)
  4-7 days                                                                4 (1.6)                 3 (1.3)               217 (6.2)
  8-14 days                                                               3 (1.2)                 0                     146 (4.2)
  ≥15vdays                                                                3 (1.2)                 0                     114 (4.2)
  Right heart failure, *n* (%)                                            1 (0.4)                 3 (1.3)               76 (2.2)
  Occurrence of nosocomial infections, *n* (%)                                                                          
  Any nosocomial infection                                                20 (7.9)                4 (1.8)               213 (6.1)
  Nosocomial pneumonia                                                    2 (0.8)                 0                     49 (1.4)
  Nosocomial sepsis                                                       0                       0                     18 (0.5)
  Nosocomial gastrointestinal infection                                   8 (3.1)                 4 (1.8)               133 (3.8)
  Other nosocomial infection                                              11 (4.3)                0                     36 (1.0)
  Specific nosocomial gastrointestinal infections                                                                       
  Suspected/confirmed norovirus infection                                 1 (0.4)                 0                     12 (0.3)
  Suspected/confirmed rotavirus infection                                 6 (2.4)                 4 (1.8)               93 (2.7)
  Suspected/confirmed. *Clostridium difficile* infection                  0                       0                     1 (\<0.1)
  Supplemental oxygen administration, *n* (%)                             59 (23.2)               72 (31.6)             1563 (45.0)
  Mean (SD) duration of supplemental oxygen administration, days          7 (18)                  3 (2)                 6 (10)
  Duration of supplemental oxygen administration (categorical), *n* (%)                                                 
  1-3 days                                                                29 (11.4)               55 (24.1)             763 (22.0)
  4-7 days                                                                20 (7.9)                13 (5.7)              474 (13.6)
  8-14 days                                                               5 (2.0)                 5 (2.0)               186 (5.4)
  ≥15 days                                                                4 (1.6)                 4 (1.6)               111 (3.2)
  Use of bronchodilatators, *n* (%)                                       206 (81.1)              211 (92.5)            2698 (77.7)
  Patient outcome at discharge, *n* (%)                                                                                 
  Complete recovery                                                       91 (35.8)               0                     1623 (46.7)
  Improvement                                                             158 (62.2)              228 (100.0)           1782 (51.3)
  Death                                                                   0                       0                     30 (0.9)
  Transfer to other hospital                                              1 (0.4)                 0                     21 (0.6)
  Unknown                                                                 4 (1.6)                 0                     18 (0.5)

ICU -- intensive care unit; LRTI -- lower respiratory tract infection.

DISCUSSION {#sec4}
==========

Approximately 22% of all episodes of acute LRTIs in children below five years of age are associated with RSV. A substantial proportion of RSV-associated morbidity occurs in the first year of life, with an incidence in infants that is twice or three times greater than is reported for children below five years overall ([@ref10]). We present the data describing a selected sample of children younger than one year of age hospitalized with LRTI during two consecutive RSV seasons in two health care centres in Lithuania and Estonia. Out of 482 children below one year of age with LRTI, RSV was confirmed in 87.3% cases at the Estonian site and in 54.2% cases at the Lithuanian site. It should be noted, that different RSV test methods were applied -- immunofluorescence and PCR in Estonia and immunochromatographic method in Lithuania.

Well-established disease- and patient-specific risk factors, including congenital heart disease, bronchopulmonary dysplasia, and premature birth, have consistently been found to increase the likelihood of a serious RSV disease. The risk of a serious RSV illness in premature infants is increased if they attend a childcare facility or share a dwelling with multiple siblings or other children. Conditions that compromise handling of respiratory tract secretions, such as congenital abnormalities of the airway and severe neuromuscular disease, are also largely believed to increase the risk of a serious RSV disease ([@ref11]--[@ref13]). The parent study reported a more severe course of RSV-related LRTI infection among premature children compared to full-term children ([@ref9]). In our sample, the established risk factors (i.e., prematurity, concomitant chronic diseases) were relatively less prevalent than in the full survey population.

We observed some differences in the management of enrolled patients between the sites, namely, the duration of hospitalisation and ICU hospitalisation, as well as duration of supplemental oxygen administration. Such findings might be influenced by the severity of the condition of the enrolled patients (e.g., there were considerably fewer alert patients on admission at the Lithuanian site compared to the Estonian site). Also, there were differences in patients' status at discharge -- about one-third of discharged patients were completely recovered in Lithuania, whereas all the discharged patients in Estonia were improved but none completely recovered. The latter difference might be related to different local clinical practices in the management of such patients and to the definition of complete recovery.

The results of this study need to be interpreted with caution. Firstly, the data were recorded in a retrospective manner which might have resulted in some recall bias. Secondly, only two health care centres (one in each country) participated in the study, therefore the reported findings might not represent the whole country.

CONCLUSIONS {#sec5}
===========

RSV was highly prevalent among children younger than one year of age hospitalized for LRTIs in Lithuania (54.2%) and Estonia (87.3%). Bronchiolitis was the most common diagnosis in hospitalized patients.
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